Generic Formulation Of Effective HIV Drug Becomes Available To Some Kenyans Through UNITAID Donation

Deutsche Welle: Kenya first in Africa to enroll new generic AIDS drug
“Kenya’s government and the global health initiative UNITAID announced Wednesday that the East African nation will make the generic version of dolutegravir [DTG] available for routine use…” (Muvunyi, 6/28).

Devex: Kenya becomes first country to debut generic HIV drug
“…DTG has been the preferred first-line treatment in the United States and Canada since 2014, a year after it came onto the market. Although some patients on the continent have accessed the more expensive version, the affordability of the generic DTG will be a ‘game changer’ in the treatment of HIV/AIDS, said Robert Matiru, UNITAID director of operations…” (Roby, 6/28).

Intellectual Property Watch: World’s Most Effective HIV Drug Rolled Out In Africa In Generic Version
“…Medical experts said the drug — produced by Indian-based generic manufacturer Eurobindo Pharma Limited — has few side effects, is easier to take than other formulations (one small tablet taken daily) in use, and that those who use it are less likely to develop resistance…” (Nzwili, 6/29).

VOA News: Kenya’s New HIV Treatment Offers Hope for Patients
“…UNITAID donated approximately 148,000 bottles of DTG to Kenya’s Health Ministry, which will cover about one percent of the patients living with HIV in the country…” (Ruvaga, 6/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.